# Harmony Biosciences Reports 30% WAKIX Revenue Growth in Q2 2026 and Releases Phase 1 BP-205 Data

> news · REPORTED · 2026-08-04

Harmony Biosciences reported Q2 2026 WAKIX net product revenue of $261.3 million, up 30% year over year with approximately 8,950 average patients, and reiterated full-year WAKIX revenue guidance of $1.0 to $1.04 billion. The company also shared favorable Phase 1 single ascending dose pharmacokinetics and tolerability data for pipeline asset BP-205, with Phase 1b and Phase 2 studies planned for 2026 to 2027.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases, including narcolepsy, for which its lead product WAKIX (pitolisant) is approved.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://ir.harmonybiosciences.com/news-releases/news-releases/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.